World's first RSV vaccine for people 60 years and older1

AREXVY helps protect against lung and lower airway infection caused by respiratory syncytial virus (RSV).2

OVER 82%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older*2

Overall efficacy in people ≥ 60 years old (n=12466): 82.6%
(96.95% CI: 57.9 to 94.1)

OVER 94%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease*2

Efficacy in participants with ≥1 comorbidity of interest (n=4937): 94.6%
(95% CI: 65.9 to 99.9)

*In a clinical study

What is RSV?

RSV is a contagious respiratory virus. It can lead to severe infections affecting the lungs and lower airways.3,4
ABOUT RSV arrow

What is AREXVY?

AREXVY is a vaccine given as a single dose used to help protect people 60 years and older from RSV.2
ABOUT AREXVY arrow

Is AREXVY for Me?

See sample questions to ask your doctor about RSV and getting vaccinated.
GET STARTED arrow

Ask your doctor about AREXVY today.

IMPORTANT SAFETY INFORMATION:2

You should not be given AREXVY if you are allergic to any of its ingredients.

Side effects: headache, muscle pain, joint pain, tiredness and pain at the injection site. This is not a full list.

Vaccination with AREXVY may not result in protection of all vaccine recipients.

Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you.

References:
  1. GSK;2023;1-9;US FDA approves GSK's Arexvy
  2. GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ; 2024. Available at https://www.medsafe.govt.nz/profs/datasheet/a/Arexvyinj.pdf (Last accessed May 2024)
  3. Papi A;N Engl J Med;2023;388;595-608
  4. Kaler J;Cureus;2023;15;1-17

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are hypersensitive to any component of this vaccine. AREXVY has risks and benefits - ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

This website is intended for residents of New Zealand only.

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional's advice.